跳至主要内容
临床试验/NCT05504902
NCT05504902Enrolling By Invitation不适用

Vibrotactile Coordinated Reset for the Treatment of Advanced Parkinson's Disease

Stanford University2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2023年8月30日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
35
试验地点
2
主要终点
Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) off medication

研究概览

简要总结

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on advanced stage Parkinson's symptoms. VCR will be administered with a device called the Stanford CR Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. Patients will be followed for two years.

详细描述

This study involves gentle vibrations delivered to the finger-tips which have been shown in pilot studies to be effective in reducing motor symptoms associated with Parkinson's Disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at the time of enrollment: 18 years of age or older
  • Idiopathic Parkinson's Symptoms between hoehn and yahr stages 2 to 4
  • Fluent in English
  • If patient is on medication that affects brain function or alters EEG activity, the patient must feel comfortable going off this medication prior to EEG recording
  • Appropriate social support if required during an off state.
  • Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.
  • Feels comfortable going off PD related medication during in person study visits.
  • Lives in the United States

排除标准

  • Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies
  • Any current drug or alcohol abuse.
  • Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.
  • Pregnancy, breast-feeding or wanting to become pregnant
  • Physical limitations unrelated to PD that would affect motor ratings
  • Brain surgery
  • Patient is unable to communicate properly with staff (i.e., severe speech problems)
  • Excessive drooling
  • A type of hair style that would impede the use of an EEG cap
  • Sensory abnormalities of the fingertips
  • Patient is taking a medication that may cause significant withdrawal effects

结局指标

主要结局

Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) off medication

时间窗: Baseline, 6 months, 12 months, 18 months, 24 months

This scale measures motor ability within Parkinson's patients. For part 3, the scales minimum values is 0 and max value is 132. Higher scores indicate more impaired motor ability, while lower scores indicate less impaired motor ability. A score of 0 indicates no motor impairment. This assessment is performed while participants are off Parkinson's-related medication.

次要结局

  • Levodopa equivalent daily dose (LEDD)(Baseline, 24 months)
  • Communicative Participation Item Bank (CPIB; Short Form)(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Parkinsons disease quality of life questionnaire-39 (PDQ-39)(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Freezing of Gait Questionnaire (FOG)(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 1(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 4(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) on medication(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 2(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Voice Handicap Index (VHI-10)(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Parkinson's disease cognitive functional rating scale (PD-CFRS)(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Spontaneous EEG beta band power(Baseline, 6 months, 12 months, 18 months, 24 months)
  • Vibratory threshold(Baseline, 6 months, 12 months, 18 months, 24 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vivek P. Buch

Protocol Director

Stanford University

研究点 (2)

Loading locations...

相似试验